IPW
CRDL

Impact Partnership Wealth’s Cardiol Therapeutics CRDL Stock Holding History

Impact Partnership Wealth’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6K Hold
10,850
– – ﹤0.01% 362
2025
Q4 		$10.3K Buy
+10,850
New +$11.4K ﹤0.01% 359

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Impact Partnership Wealth's CRDL Position: Q1 2026 in Review

Impact Partnership Wealth held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 10,850 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #362.

Impact Partnership Wealth first reported a position in CRDL in Q4 2025 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Impact Partnership Wealth held 10,850 shares of Cardiol Therapeutics worth $14.6K as of Q1 2026.
  • Impact Partnership Wealth left its Cardiol Therapeutics share count unchanged in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Impact Partnership Wealth's portfolio in Q1 2026, its #362 holding.
  • Impact Partnership Wealth first reported a position in Cardiol Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Impact Partnership Wealth's 13F filing for Q1 2026, filed 23 Apr 2026.